Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rigosertib Plus Nivolumab in Stage IV KRAS+ Lung Adenocarcinoma
NCT04263090Phase 2Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Jun 2020
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rigosertib in non-small cell lung cancer (NSCLC), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoints: Maximal Tolerated Dose at 28 days and Overall Response Rate at 2 years. Started Jun 2020; status: completed.
02
Drugs
rigosertib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04263090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04263090.